Home Menu

Site Navigation



NeuroTalk Support Groups > > >

Evaluating Risk versus Benefit of Drugs for MS

Reply
 
Thread Tools Display Modes
Old 10-02-2006, 10:41 PM #1
Harry Z Harry Z is offline
Member
  
Join Date: Sep 2006
Location: London, Canada
Posts: 241
15 yr Member
Harry Z Harry Z is offline
Member
 
Join Date: Sep 2006
Location: London, Canada
Posts: 241
15 yr Member
Default
Quote:
Conclusion: Given the difference in baseline risk and severity levels across studies, ARR is the appropriate way to compare DMDs in the absence of head-to-head clinical trials. Results based on ARR showed that IFNB-1a sc has comparable therapeutic effect on efficacy measures when compared to natalizumab.
I'm sure when the insurance companies' docs read this kind of report, they aren't exactly going to be eager in recommending that Tysabri be covered without a lot of red tape.

Harry
Harry Z is offline   Reply With QuoteReply With Quote
Reply

« Previous Thread | Next Thread »

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts
BB code is On
Smilies are On
[IMG] code is On
HTML code is Off


All times are GMT -5. The time now is 01:49 PM.


Powered by vBulletin • Copyright ©2000 - 2025, Jelsoft Enterprises Ltd.

vBulletin Optimisation provided by vB Optimise (Lite) - vBulletin Mods & Addons Copyright © 2025 DragonByte Technologies Ltd.
 

NeuroTalk Forums

Helping support those with neurological and related conditions.

 

All posts copyright their original authors.

The material on this site is for informational purposes only,
and is not a substitute for medical advice, diagnosis or treatment
provided by a qualified health care provider.

Always consult your doctor before trying anything you read here.

Home